Boehringer Ingelheim Corporate News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Approval for Aservo EquiHaler equine asthma therapy
Boehringer Ingelheim receives approval for Aservo ® EquiHaler®, industry first therapy for severe equine asthmaAservo ®EquiHaler® (ciclesonide inhalation solution) is a result of synergies between human pharma and animal health businessesThe inhaler addresses an unmet need in the equine segmentThe company continues to set new standards of care to strengthen its commitment to animal welfare (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 4, 2020 Category: Research Source Type: news

Fibrotic diseases partnership with Enleofen
Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases  Acquisition of worldwide exclusive rights adds extensive anti-IL-11 platform to Boehringer Ingelheim pipeline portfolio  Boehringer Ingelheim aims to develop therapies for multiple fibrotic human disorders, including non-alcoholic steatohepatitis (NASH) and interstitial lung diseases (ILDs)Singapore-based Enleofen to receive in excess of one billion USD per product in upfront and success-based development and commercialization milestones (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 9, 2020 Category: Research Source Type: news

DiaTEC new purification technology Ingelvac CircoFLEX
Boehringer Ingelheim introduces DiaTEC, a new and proprietary purification technology for Ingelvac CircoFLEX ®Ingelvac CircoFLEX ® was the first PCV2 vaccine that could be freshly mixed with an M hyo vaccine to address two critical swine pathogens in one injection.With DiaTEC, a new and proprietary diafiltration technology, Ingelvac CircoFLEX ® becomes the first and only non-virucidal PCV2 vaccine for improved capabilities to be freshly mixed on farm.Since its launch, Ingelvac CircoFLEX ® has been used to protect 3 billion pigs in more than 68 countries around the world, based on vaccine sales. (Source: Boehringer Inge...
Source: Boehringer Ingelheim Corporate News - January 3, 2020 Category: Research Source Type: news

biopharmaceuticals-in-china
Milestone for Biopharmaceuticals in ChinaBoehringer Ingelheim manufactures first biopharmaceutical approved in China under new MAH contract manufacturing regulatory systemBoehringer Ingelheim ’s contract manufacturing business partners with BeiGene, Ltd. Contribution to China ’s healthcare system by strengthening  the domestic biopharmaceutical R&D of Boehringer Ingelheim ’s partners (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 30, 2019 Category: Research Source Type: news

discontinuation of development of BI 1467335 for NASH
Boehringer Ingelheim discontinues development of BI 1467335 for NASHBI 1467335 was part of Boehringer Ingelheim ’s growing NASH R&D pipeline portfolio  Study of BI 1467335 in diabetic retinopathy will be continued (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 18, 2019 Category: Research Source Type: news

EMPERIAL-heart-failure-toplineresults
Boehringer Ingelheim and Lilly provide update on empagliflozin phase III exercise ability studies in chronic heart failure (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 13, 2019 Category: Research Source Type: news

Boehringer Ingelheim annouces 2020 BVDzero Case Awards
Boehringer Ingelheim announces BVDzero Case Awards 2020Boehringer Ingelheim will award a total prize of 15,000 euros to the top 10 clinical cases entered.Applications can be submitted to theBVDzero website. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 9, 2019 Category: Research Source Type: news

EMPRISE-interim-analysis
Interim analysis from EMPRISE real-world study shows empagliflozin decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonistsThis analysis on effectiveness also shows empagliflozin was associated with a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors or GLP-1 receptor agonists1  A second analysis on healthcare resource utilisation shows empagliflozin was associated with a reduced risk in all-cause hospitalisations compared with DPP-4 inhibitors2 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 17, 2019 Category: Research Source Type: news

Empulse
Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart failure who have been stabilisedEMPULSE is a superiority study that will assess the clinical benefit, safety and tolerability of 10 mg daily empagliflozin in acute heart failure1  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 12, 2019 Category: Research Source Type: news

New African Swine Fever Manual published
The new African Swine Fever Manual publishedBoehringer Ingelheim joins hands with leading veterinarians to fight African swine feverThe company donates 500  copies to industry partners (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 5, 2019 Category: Research Source Type: news

New Focus for Boehringer Ingelheim and Lilly Alliance
Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance ®Alliance to focus combined expertise and investment to maximise Jardiance ®for people with type 2 diabetes, heart failure, and chronic kidney diseaseAlliance to continue to include three product families – empagliflozin, linagliptin  and insulin glargine (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 4, 2019 Category: Research Source Type: news

first pan-KRAS inhibitor advances to clinical testing
Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing  Results were presented from the company ’s pan-KRAS program including BI 1701963, which is being investigated alone and in combination with MEK inhibition in an ongoing Phase I clinical study in cancer patientsAround 15% off all cancers can potentially be blocked by this compound, targeting all major oncogenic KRAS mutations   Dual KRAS pathway blockade combining pan-KRAS and MEK inhibition has potential to further enhance efficacy (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 29, 2019 Category: Research Source Type: news

Boehringer Ingelheim_theDefeatNCD_Partnership_fight_NCDs
Boehringer Ingelheim joins forces with The Defeat-NCD Partnership to fight non-communicable diseases  41 million people die each year caused by non-communicable diseases (NCDs) - more than three quarters occur in low- and middle-income countries   Together with The Defeat-NCD Partnership, Boehringer Ingelheim aims to address key access to healthcare issues related to NCDs    Non-communicable diseases make up 85 per cent of Boehringer Ingelheim ’s medicines portfolio (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 29, 2019 Category: Research Source Type: news

cystic fibrosis phase II trial
Boehringer Ingelheim Announces First Patient Enrolled in Phase II Trial of Novel Cystic Fibrosis Treatment (BALANCE-CFTM 1)Investigational compound BI ENaC inhibitor delivered twice daily via the Respimat ®, a handheld inhaler  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 16, 2019 Category: Research Source Type: news

Breakthrough-Therapy-Designation-Progressive-Fibrosing-ILD
FDA Grants nintedanib Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive PhenotypeThe designation was supported by results from the Phase III INBUILD ® study that met its primary endpoint and was recently published in the New England Journal of Medicine (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 10, 2019 Category: Research Source Type: news